Tiziana Life Sciences (TLSA) Competitors $1.46 -0.15 (-9.32%) Closing price 04:00 PM EasternExtended Trading$1.50 +0.04 (+2.81%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLSA vs. DSGN, CYRX, AVTE, ACRS, and GYREShould you buy Tiziana Life Sciences stock or one of its competitors? MarketBeat compares Tiziana Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tiziana Life Sciences include Design Therapeutics (DSGN), CryoPort (CYRX), Aerovate Therapeutics (AVTE), Aclaris Therapeutics (ACRS), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry. TLSA vs. DSGNTLSA vs. CYRXTLSA vs. AVTETLSA vs. ACRSTLSA vs. GYREHow does Tiziana Life Sciences compare to Design Therapeutics?Tiziana Life Sciences (NASDAQ:TLSA) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings. Which has higher valuation and earnings, TLSA or DSGN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTiziana Life SciencesN/AN/A-$18.43MN/AN/ADesign TherapeuticsN/AN/A-$69.79M-$1.20N/A Do insiders & institutionals have more ownership in TLSA or DSGN? 56.6% of Design Therapeutics shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by insiders. Comparatively, 23.5% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate TLSA or DSGN? Design Therapeutics has a consensus price target of $16.50, indicating a potential upside of 49.86%. Given Design Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Design Therapeutics is more favorable than Tiziana Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Design Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88 Does the media prefer TLSA or DSGN? In the previous week, Design Therapeutics had 5 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 12 mentions for Design Therapeutics and 7 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 0.59 beat Design Therapeutics' score of 0.36 indicating that Tiziana Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tiziana Life Sciences 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Design Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Is TLSA or DSGN more profitable? Tiziana Life Sciences' return on equity of 0.00% beat Design Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tiziana Life SciencesN/A N/A N/A Design Therapeutics N/A -33.07%-31.29% Which has more volatility and risk, TLSA or DSGN? Tiziana Life Sciences has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.73, suggesting that its share price is 73% more volatile than the broader market. SummaryDesign Therapeutics beats Tiziana Life Sciences on 7 of the 12 factors compared between the two stocks.How does Tiziana Life Sciences compare to CryoPort?Tiziana Life Sciences (NASDAQ:TLSA) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends. Do institutionals and insiders have more ownership in TLSA or CYRX? 92.9% of CryoPort shares are held by institutional investors. 39.8% of Tiziana Life Sciences shares are held by insiders. Comparatively, 10.0% of CryoPort shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has stronger valuation and earnings, TLSA or CYRX? CryoPort has higher revenue and earnings than Tiziana Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTiziana Life SciencesN/AN/A-$18.43MN/AN/ACryoPort$176.18M4.07$78.30M$1.3510.53 Does the media favor TLSA or CYRX? In the previous week, Tiziana Life Sciences had 3 more articles in the media than CryoPort. MarketBeat recorded 7 mentions for Tiziana Life Sciences and 4 mentions for CryoPort. Tiziana Life Sciences' average media sentiment score of 0.59 beat CryoPort's score of 0.48 indicating that Tiziana Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tiziana Life Sciences 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CryoPort 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, TLSA or CYRX? Tiziana Life Sciences has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, CryoPort has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Is TLSA or CYRX more profitable? CryoPort has a net margin of 41.57% compared to Tiziana Life Sciences' net margin of 0.00%. Tiziana Life Sciences' return on equity of 0.00% beat CryoPort's return on equity.Company Net Margins Return on Equity Return on Assets Tiziana Life SciencesN/A N/A N/A CryoPort 41.57%-7.92%-4.79% Do analysts prefer TLSA or CYRX? CryoPort has a consensus target price of $14.69, suggesting a potential upside of 3.29%. Given CryoPort's stronger consensus rating and higher probable upside, analysts plainly believe CryoPort is more favorable than Tiziana Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00CryoPort 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 SummaryCryoPort beats Tiziana Life Sciences on 8 of the 13 factors compared between the two stocks.How does Tiziana Life Sciences compare to Aerovate Therapeutics?Tiziana Life Sciences (NASDAQ:TLSA) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Which has preferable valuation and earnings, TLSA or AVTE? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTiziana Life SciencesN/AN/A-$18.43MN/AN/AAerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A Does the media refer more to TLSA or AVTE? In the previous week, Tiziana Life Sciences had 7 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 7 mentions for Tiziana Life Sciences and 0 mentions for Aerovate Therapeutics. Tiziana Life Sciences' average media sentiment score of 0.59 beat Aerovate Therapeutics' score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the media. Company Overall Sentiment Tiziana Life Sciences Positive Aerovate Therapeutics Neutral Do analysts prefer TLSA or AVTE? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is TLSA or AVTE more profitable? Tiziana Life Sciences' return on equity of 0.00% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tiziana Life SciencesN/A N/A N/A Aerovate Therapeutics N/A -90.19%-77.47% Which has more volatility & risk, TLSA or AVTE? Tiziana Life Sciences has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. SummaryTiziana Life Sciences beats Aerovate Therapeutics on 6 of the 7 factors compared between the two stocks.How does Tiziana Life Sciences compare to Aclaris Therapeutics?Aclaris Therapeutics (NASDAQ:ACRS) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment. Does the media favor ACRS or TLSA? In the previous week, Tiziana Life Sciences had 5 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 7 mentions for Tiziana Life Sciences and 2 mentions for Aclaris Therapeutics. Tiziana Life Sciences' average media sentiment score of 0.59 beat Aclaris Therapeutics' score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tiziana Life Sciences 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in ACRS or TLSA? 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 5.6% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is ACRS or TLSA more profitable? Tiziana Life Sciences has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Tiziana Life Sciences' return on equity of 0.00% beat Aclaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aclaris Therapeutics-832.58% -55.89% -38.49% Tiziana Life Sciences N/A N/A N/A Which has more risk and volatility, ACRS or TLSA? Aclaris Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Which has higher valuation and earnings, ACRS or TLSA? Tiziana Life Sciences has lower revenue, but higher earnings than Aclaris Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclaris Therapeutics$7.83M80.98-$64.92M-$0.56N/ATiziana Life SciencesN/AN/A-$18.43MN/AN/A Do analysts prefer ACRS or TLSA? Aclaris Therapeutics currently has a consensus price target of $11.29, indicating a potential upside of 148.58%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aclaris Therapeutics is more favorable than Tiziana Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclaris Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.00Tiziana Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SummaryAclaris Therapeutics and Tiziana Life Sciences tied by winning 7 of the 14 factors compared between the two stocks.How does Tiziana Life Sciences compare to Gyre Therapeutics?Gyre Therapeutics (NASDAQ:GYRE) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations. Do insiders and institutionals believe in GYRE or TLSA? 24.0% of Gyre Therapeutics shares are owned by institutional investors. 10.0% of Gyre Therapeutics shares are owned by insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to GYRE or TLSA? In the previous week, Tiziana Life Sciences had 4 more articles in the media than Gyre Therapeutics. MarketBeat recorded 7 mentions for Tiziana Life Sciences and 3 mentions for Gyre Therapeutics. Tiziana Life Sciences' average media sentiment score of 0.59 beat Gyre Therapeutics' score of -0.32 indicating that Tiziana Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Tiziana Life Sciences 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, GYRE or TLSA? Gyre Therapeutics has a beta of 2.03, suggesting that its share price is 103% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Is GYRE or TLSA more profitable? Tiziana Life Sciences has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Tiziana Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Gyre Therapeutics-5.44% 3.13% 2.67% Tiziana Life Sciences N/A N/A N/A Do analysts rate GYRE or TLSA? Gyre Therapeutics currently has a consensus target price of $17.00, indicating a potential upside of 175.08%. Given Gyre Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Gyre Therapeutics is more favorable than Tiziana Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00Tiziana Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has preferable valuation & earnings, GYRE or TLSA? Gyre Therapeutics has higher revenue and earnings than Tiziana Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGyre Therapeutics$116.59M5.14$5.03M-$0.09N/ATiziana Life SciencesN/AN/A-$18.43MN/AN/A SummaryGyre Therapeutics beats Tiziana Life Sciences on 9 of the 13 factors compared between the two stocks. Get Tiziana Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLSA vs. The Competition ExportMetricTiziana Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$185.80M$3.36B$6.34B$12.28BDividend YieldN/A2.32%2.80%5.36%P/E RatioN/A19.0220.9225.48Price / SalesN/A278.81521.1573.33Price / CashN/A125.3543.1855.00Price / BookN/A6.909.987.01Net Income-$18.43M$24.23M$3.55B$335.16M7 Day Performance0.69%0.65%0.40%-0.30%1 Month Performance18.70%-0.55%-0.04%1.14%1 Year Performance2.82%63.42%34.95%34.69% Tiziana Life Sciences Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLSATiziana Life Sciences0.9158 of 5 stars$1.46-9.3%N/A+7.3%$185.80MN/AN/A8News CoverageHigh Trading VolumeDSGNDesign Therapeutics3.3254 of 5 stars$10.76+0.6%$16.50+53.3%+202.5%$672.44MN/AN/A40Options VolumeHigh Trading VolumeCYRXCryoPort2.8676 of 5 stars$13.22-0.7%$14.44+9.2%+108.8%$666.44M$176.18M9.791,186Analyst ForecastOptions VolumeAVTEAerovate TherapeuticsN/A$22.01-5.8%N/A+194.9%$637.96MN/AN/A20High Trading VolumeACRSAclaris Therapeutics2.2245 of 5 stars$4.48+1.7%$11.29+152.2%+235.6%$624.98M$7.83MN/A100Gap Down Related Companies and Tools Related Companies DSGN Competitors CYRX Competitors AVTE Competitors ACRS Competitors GYRE Competitors CRMD Competitors SLDB Competitors ZVRA Competitors TLRY Competitors CTMX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLSA) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Tiziana Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
